Several other brokerages also recently issued reports on SIEN. UBS Group decreased their target price on Sientra from $10.00 to $8.00 and set a buy rating on the stock in a research note on Tuesday, March 29th. Stifel Nicolaus reduced their price objective on shares of Sientra from $11.00 to $7.00 and set a buy rating on the stock in a research report on Thursday, March 24th. Lake Street Capital started coverage on shares of Sientra in a research report on Thursday, April 14th. They set a buy rating and a $8.00 target price for the company. Colliers Securities reiterated a buy rating on shares of Sientra in a report on Tuesday, March 22nd. Finally, Canaccord Genuity Group decreased their price target on shares of Sientra from $10.00 to $8.00 and set a buy rating on the stock in a research note on Tuesday, March 29th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Sientra presently has a consensus rating of Buy and an average target price of $7.75.
Shares of SIEN stock opened at $1.41 on Tuesday. The company has a market capitalization of $87.93 million, a price-to-earnings ratio of -0.82 and a beta of 2.11. Sientra has a one year low of $1.22 and a one year high of $9.14. The company’s fifty day moving average price is $2.02 and its 200-day moving average price is $3.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.76 and a quick ratio of 1.10.
Several institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. increased its holdings in shares of Sientra by 230.9% in the 1st quarter. Advisor Group Holdings Inc. now owns 11,930 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 8,325 shares during the last quarter. Barclays PLC increased its holdings in shares of Sientra by 168.0% in the 4th quarter. Barclays PLC now owns 70,474 shares of the medical instruments supplier’s stock worth $259,000 after buying an additional 44,181 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Sientra by 1.8% in the 4th quarter. BlackRock Inc. now owns 3,693,642 shares of the medical instruments supplier’s stock worth $13,556,000 after buying an additional 66,003 shares during the last quarter. Paradigm Financial Partners LLC bought a new stake in shares of Sientra in the 4th quarter worth about $50,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Sientra by 190.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 261,687 shares of the medical instruments supplier’s stock worth $961,000 after buying an additional 171,598 shares during the last quarter. Hedge funds and other institutional investors own 82.42% of the company’s stock.
About Sientra (Get Rating)
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
- Get a free copy of the StockNews.com research report on Sientra (SIEN)
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.